New and emerging treatment options for biliary tract cancer

References

• ShaibYEl-SeragHBThe epidemiology of cholangiocarcinomaSemin Liver Dis200424211512515192785
   PubMed Web of Science ®Google Scholar
• SiegelRNaishadhamDJemalACancer statistics, 2013CA Cancer J Clin2013631113023335087
   PubMed Web of Science ®Google Scholar
• PatelTIncreasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United StatesHepatology20013361353135711391522
   PubMed Web of Science ®Google Scholar
• HezelAFDeshpandeVZhuAXGenetics of biliary tract cancers and emerging targeted therapiesJ Clin Oncol201028213531354020547994
   PubMed Web of Science ®Google Scholar
• De GroenPCGoresGJLaRussoNFGundersonLLNagorneyDMBiliary tract cancersN Engl J Med1999341181368137810536130
   PubMed Web of Science ®Google Scholar
• KornfeldDEkbomAIhreTSurvival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. A population-based studyScand J Gastroenterol19973210104210459361178
   PubMed Web of Science ®Google Scholar
• FavaGLorenziniIMolecular pathogenesis of cholangiocarcinomaInt J Hepatol2012201263054321994887
   PubMedGoogle Scholar
• ChaiteerakijRYangJDHarmsenWSRisk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer riskHepatology201357264865523055147
   PubMed Web of Science ®Google Scholar
• YuTHYuanRHChenYLYangWCHsuHCJengYMViral hepatitis is associated with intrahepatic cholangiocarcinoma with cholangiolar differentiation and N-cadherin expressionMod Pathol201124681081921423153
   PubMed Web of Science ®Google Scholar
• GlimeliusBHoffmanKSjödénPOChemotherapy improves survival and quality of life in advanced pancreatic and biliary cancerAnn Oncol1996765936008879373
   PubMed Web of Science ®Google Scholar
• GallardoJORubioBFodorMA phase II study of gemcitabine in gallbladder carcinomaAnn Oncol200112101403140611762811
   PubMed Web of Science ®Google Scholar
• PenzMKornekGVRadererMPhase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancerAnn Oncol200112218318611300321
   PubMed Web of Science ®Google Scholar
• ValleJWasanHPalmerDHABC-02 Trial InvestigatorsCisplatin plus gemcitabine versus gemcitabine for biliary tract cancerN Engl J Med2010362141273128120375404
   PubMed Web of Science ®Google Scholar
• AndréTTournigandCRosmorducOGERCOR GroupGemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR studyAnn Oncol20041591339134315319238
   PubMed Web of Science ®Google Scholar
• PrachtMLe RouxGSulpiceLChemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four yearsChemotherapy201258213414122572213
   PubMed Web of Science ®Google Scholar
• ZaberniggAGiesingerJMPallGQuality of life across chemotherapy lines in patients with cancers of the pancreas and biliary tractBMC Cancer20121239022950826
   PubMed Web of Science ®Google Scholar
• GarrawayLABaselgaJWhole-genome sequencing and cancer therapy: is too much ever enough?Cancer Discov20122976676822969114
   PubMed Web of Science ®Google Scholar
• BiankinAVWaddellNKassahnKSAustralian Pancreatic Cancer Genome InitiativePancreatic cancer genomes reveal aberrations in axon guidance pathway genesNature2012491742439940523103869
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas NetworkComprehensive molecular characterization of human colon and rectal cancerNature2012487740733033722810696
   PubMed Web of Science ®Google Scholar
• DulakAMStojanovPPengSExome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexityNat Genet201345547848623525077
   PubMed Web of Science ®Google Scholar
• VogelsteinBPapadopoulosNVelculescuVEZhouSDiazLAKinzlerKWCancer genome landscapesScience201333961271546155823539594
   PubMed Web of Science ®Google Scholar
• OngCKSubimerbCPairojkulCExome sequencing of liver fluke-associated cholangiocarcinomaNat Genet201244669069322561520
   PubMed Web of Science ®Google Scholar
• RashidAUekiTGaoYTK-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in ChinaClin Cancer Res20028103156316312374683
   PubMed Web of Science ®Google Scholar
• SutoTHabanoWSugaiTAberrations of the K-ras, p53, and APC genes in extrahepatic bile duct cancerJ Surg Oncol200073315816310738270
   PubMed Web of Science ®Google Scholar
• TannapfelABenickeMKatalinicAFrequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liverGut200047572172711034592
   PubMed Web of Science ®Google Scholar
• TannapfelASommererFBenickeMMutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinomaGut200352570671212692057
   PubMed Web of Science ®Google Scholar
• WatanabeHDateKItoiTHistological and genetic changes in malignant transformation of gallbladder adenomaAnn Oncol199910Suppl 413613910436806
   PubMed Web of Science ®Google Scholar
• HanadaKTsuchidaAIwaoTGene mutations of K-ras in gallbladder mucosae and gallbladder carcinoma with an anomalous junction of the pancreaticobiliary ductAm J Gastroenterol19999461638164210364037
   PubMed Web of Science ®Google Scholar
• ChapmanPBHauschildARobertCBRIM-3 Study GroupImproved survival with vemurafenib in melanoma with BRAF V600E mutationN Engl J Med2011364262507251621639808
   PubMed Web of Science ®Google Scholar
• CurtinJAFridlyandJKageshitaTDistinct sets of genetic alterations in melanomaN Engl J Med2005353202135214716291983
   PubMed Web of Science ®Google Scholar
• PaiRKMojtahedKPaiRKMutations in the RAS/RAF/MAP kinase pathway commonly occur in gallbladder adenomas but are uncommon in gallbladder adenocarcinomasAppl Immunohistochem Mol Morphol201119213314021307665
   PubMedGoogle Scholar
• GoldenbergDRosenbaumEArganiPThe V599E BRAF mutation is uncommon in biliary tract cancersMod Pathol200417111386139115181454
   PubMed Web of Science ®Google Scholar
• PignochinoYSarottoIPeraldo-NeiaCTargeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomasBMC Cancer20101063121087480
   PubMed Web of Science ®Google Scholar
• WhelerJJFalchookGSTsimberidouAMAberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapyAnn Oncol201324383884223139256
   PubMed Web of Science ®Google Scholar
• LeoneFCavalloniGPignochinoYSomatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinomaClin Cancer Res20061261680168516551849
   PubMed Web of Science ®Google Scholar
• GwakGYYoonJHShinCMDetection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomasJ Cancer Res Clin Oncol20051311064965216032426
   PubMed Web of Science ®Google Scholar
• VossJSHoltegaardLMKerrSEMolecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisionsHum Pathol20134471216122223391413
   PubMed Web of Science ®Google Scholar
• DeshpandeVNduagubaAZimmermanSMMutational profiling reveals PIK3CA mutations in gallbladder carcinomaBMC Cancer2011116021303542
   PubMed Web of Science ®Google Scholar
• XuRFSunJPZhangSRKRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patientsBiomed Pharmacother2011651222621051183
   PubMed Web of Science ®Google Scholar
• BorgerDRTanabeKKFanKCFrequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotypingOncologist2012171727922180306
   PubMed Web of Science ®Google Scholar
• KippBRVossJSKerrSEIsocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinomaHum Pathol201243101552155822503487
   PubMed Web of Science ®Google Scholar
• PrensnerJRChinnaiyanAMMetabolism unhinged: IDH mutations in cancerNat Med201117329129321383741
   PubMed Web of Science ®Google Scholar
• LeeJParkSHChangHMGemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 studyLancet Oncol201213218118822192731
   PubMed Web of Science ®Google Scholar
• MalkaDCerveraPHeuteau-FoulonSGemcitabine and oxalipla-tin (GEMOX) alone or with cetuximab in first-line treatment of advanced biliary cancers (ABC): exploratory analyses according to tumor KRAS/BRAF mutations and EGFR expression in a randomized phase II trial (BINGO) [abstract]J Clin Oncol201331Suppl4127
   Google Scholar
• GruenbergerBSchuellerJHeubrandtnerUCetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 studyLancet Oncol201011121142114821071270
   PubMed Web of Science ®Google Scholar
• SohalDavendraA phase II trial of gemcitabine, irinotecan, and panitumumab in advanced cholangiocarcinoma, with correlative analysis of EGFR, KRAS, and BRAF: An interim report2012 ASCO abstract
   Google Scholar
• ChenLTChenJSChaoYKRAS mutation status-stratified randomized phase II trial of GEMOX with and without cetuximab in advanced biliary tract cancer (ABTC): the TCOG T1210 trial [abstract]J Clin Oncol201331Suppl4018
   Google Scholar
• JensenLHLindebjergJPloenJHansenTFJakobsenAPhase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancerAnn Oncol20122392341234622367707
   PubMed Web of Science ®Google Scholar
• SohalDPMetzJMSunWToxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancerCancer Chemother Pharmacol20137161485149123532207
   PubMed Web of Science ®Google Scholar
• TolJPuntCJMonoclonal antibodies in the treatment of metastatic colorectal cancer: a reviewClin Ther201032343745320399983
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med2004350232335234215175435
   PubMed Web of Science ®Google Scholar
• HidaYMoritaTFujitaMVascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomasAnticancer Res1999193B2257226010472340
   PubMed Web of Science ®Google Scholar
• ZhuAXMeyerhardtJABlaszkowskyLSEfficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 studyLancet Oncol2010111485419932054
   PubMed Web of Science ®Google Scholar
• El-KhoueiryABRankinCJBen-JosefESWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinomaInvest New Drugs20123041646165121748296
   PubMed Web of Science ®Google Scholar
• BengalaCBertoliniFMalavasiNSorafenib in patients with advanced biliary tract carcinoma: a phase II trialBr J Cancer20101021687219935794
   PubMed Web of Science ®Google Scholar
• YiJHThongprasertSLeeJA phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational studyEur J Cancer201248219620122176869
   PubMed Web of Science ®Google Scholar
• LorussoPMAdjeiAAVarterasianMPhase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignanciesJ Clin Oncol200523235281529316009947
   PubMed Web of Science ®Google Scholar
• YehTCMarshVBernatBABiological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitorClin Cancer Res20071351576158317332304
   PubMed Web of Science ®Google Scholar
• Bekaii-SaabTPhelpsMALiXMulti-institutional phase II study of selumetinib in patients with metastatic biliary cancersJ Clin Oncol201129172357236321519026
   PubMed Web of Science ®Google Scholar
• NakazawaKDobashiYSuzukiSFujiiHTakedaYOoiAAmplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancersJ Pathol2005206335636515892172
   PubMed Web of Science ®Google Scholar
• RamanathanRKBelaniCPSinghDAA phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancerCancer Chemother Pharmacol200964477778319169683
   PubMed Web of Science ®Google Scholar
• LubnerSJMahoneyMRKolesarJLReport of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium studyJ Clin Oncol201028213491349720530271
   PubMed Web of Science ®Google Scholar
• MiuraKShirasakaTYamaueHSasakiIS-1 as a core anticancer fluoropyrimidine agentExpert Opin Drug Deliv20129327328622235991
   PubMed Web of Science ®Google Scholar
• MorizaneCOkusakaTMizusawaJRandomized phase II trial of gemcitabine plus S-1 combination therapy versus S-1 in advanced biliary tract cancer: results of the Japan Clinical Oncology Group study (JCOG0805) [abstract]J Clin Oncol2012Suppl 4255
   Web of Science ®Google Scholar
• PhilipPAMahoneyMRAllmerCPhase II study of erlotinib in patients with advanced biliary cancerJ Clin Oncol200624193069307416809731
   PubMed Web of Science ®Google Scholar
• FlahertyKTRobertCHerseyPMETRIC Study GroupImproved survival with MEK inhibition in BRAF-mutated melanomaN Engl J Med2012367210711422663011
   PubMed Web of Science ®Google Scholar
• MiyamotoMOjimaHIwasakiMPrognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinomaBr J Cancer2011105113113821673683
   PubMed Web of Science ®Google Scholar
• AishimaSITaguchiKISugimachiKShimadaMSugimachiKTsuneyoshiMc-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinomaHistopathology200240326927811895493
   PubMed Web of Science ®Google Scholar
• YoshikawaDOjimaHKokubuAVandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinomaBr J Cancer200910081257126619319137
   PubMed Web of Science ®Google Scholar
• RohleDPopovici-MullerJPalaskasNAn inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cellsScience2013340613262663023558169
   PubMed Web of Science ®Google Scholar
• WangFTravinsJDeLaBarreBTargeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiationScience2013340613262262623558173
   PubMed Web of Science ®Google Scholar
• KohnoTIchikawaHTotokiYKIF5B-RET fusions in lung adenocarcinomaNat Med201218337537722327624
   PubMed Web of Science ®Google Scholar